THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.
Initial public offer of equity shares on the main board of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE", and together with BSE, the "Stock Exchanges") in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").

(Please scan the QR code to view the RHP)

Fabtech

FABTECH TECHNOLOGIES LIMITED

Fabtech Technologies Limited (the "**Issuer**" or the "**Company**") was incorporated under the Companies Act, 2013 as a private limited company under the name and style of *'Globeroute Ventures Private Limited'* pursuant a certificate of incorporation dated October 26, 2018 issued by the Registrar of Companies, Central Registration Centre. Subsequently, pursuant to resolutions passed by our Board of Directors in their meeting held on December 12, 2020 and by our Shareholders in the Extra-Ordinary General meeting held on December 30, 2020, the name of our Company was changed to *'Fabtech Technologies Private Limited'* and a fresh certificate of incorporation dated January 21, 2021 was issued by the Registrar of Companies, Maharashtra at Mumbai. The name of our Company was changed to expand the scope of services provided by our Company and for securing better overseas prospects, and to give effect to the order dated November 19, 2020 passed by the National Company Law Tribunal having its bench at Mumbai approving inter alia, demerger of the export division of Fabtech Technologies International Private Limited *(formerly known as Fabtech Technologies International Limited)* into our Company. Further, pursuant to resolutions passed by our Board of Directors in their meeting held on March 27, 2024 and by our Shareholders in the Extra-Ordinary General meeting held on April 3, 2024, our Company was converted into a public limited company, consequent to which its name was changed to *'Fabtech Technologies Limited'*, and a fresh certificate of incorporation dated July 24, 2024, consequent to such conversion was issued by the Registrar of Companies, Central Processing Centre. For further details, including in relation to changes in name and registered office of our Company, see *"History and Certain Corporate Matters"* on page 250 of the red herring prospectus dated September 22, 2025 ("**RHP**") filed with the RoC.

Registered Office: 715, Janki Centre, Off. Veera Desai Road, Andheri West, Mumbai - 400 053, Maharashtra, India; **Telephone:** +91 226 159 2900;
Corporate Office ***(where books of accounts are maintained)***: 1st Floor, ABR Emerald, Plot No D8, Street 16, MIDC Andheri East, Chakala MIDC, Mumbai – 400 093, Maharashtra, India; **Telephone:** +91 226 554 0300;
Website: www.fabtechnologies.com; **E-mail:** cs@fabtechnologies.com; **Contact Person:** Neetu Sunil Buchasia, Company Secretary and Compliance Officer; **Corporate Identity Number:** U74999MH2018PLC316357

OUR PROMOTERS: AASIF AHSAN KHAN, HEMANT MOHAN ANAVKAR, AARIF AHSAN KHAN AND MANISHA HEMANT ANAVKAR

INITIAL PUBLIC OFFERING OF UP TO 1,20,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ [•] LAKHS ("ISSUE"). THE ISSUE SHALL CONSTITUTE [●]% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE ISSUE INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AGGREGATING UP TO ₹ 100.00 LAKHS (CONSTITUTING UP TO [●]% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE ISSUE LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER, MAY OFFER A DISCOUNT OF UP TO [●]% (EQUIVALENT OF ₹9 PER EQUITY SHARE) ON THE ISSUE PRICE TO ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

PRICE BAND: ₹181 TO ₹191 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH.
THE FLOOR PRICE IS 18.1 TIMES THE FACE VALUE OF THE EQUITY SHARES AND
THE CAP PRICE IS 19.1 TIMES THE FACE VALUE OF THE EQUITY SHARES.
BIDS CAN BE MADE FOR A MINIMUM OF 75 EQUITY SHARES AND IN MULTIPLES OF 75 EQUITY SHARES THEREAFTER.
THE PRICE TO EARNINGS RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE LOWER END OF THE PRICE BAND (i.e FLOOR PRICE) IS 12.62 TIMES AND AT THE UPPER END OF THE PRICE BAND (i.e CAP PRICE) IS 13.32 TIMES.
A DISCOUNT OF ₹ 9 PER EQUITY SHARE IS BEING OFFERED TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION.

BID/ISSUE PROGRAMME	
	ANCHOR INVESTOR BIDDING DATE: FRIDAY, SEPTEMBER 26, 2025
	BID/ISSUE OPENS ON MONDAY, SEPTEMBER 29, 2025
	BID/ ISSUE CLOSES ON WEDNESDAY, OCTOBER 1, 2025^

^ UPI mandate end time and date shall be at 5:00 pm on the Bid/Issue Closing Date.

We are a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. We offer services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies.

THE ISSUE IS BEING MADE THROUGH THE BOOK BUILDING PROCESS IN ACCORDANCE WITH REGULATION 6(1) OF THE SEBI ICDR REGULATIONS 2018.
THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON THE MAIN BOARD PLATFORM OF BSE AND NSE.
NATIONAL STOCK EXCHANGE OF INDIA LIMITED SHALL BE THE DESIGNATED STOCK EXCHANGE.
• QIB PORTION: NOT MORE THAN 50% OF THE NET ISSUE • NON-INSTITUTIONAL PORTION: NOT LESS THAN 15% OF THE NET ISSUE
• RETAIL PORTION: NOT LESS THAN 35% OF THE NET ISSUE • EMPLOYEE RESERVATION PORTION: UP TO [●] EQUITY SHARES AGGRREGATING UP TO ₹ 100.00 LAKHS.

IN MAKING AN INVESTMENT DECISION AND PURCHASE IN THE ISSUE, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RHP AND THE TERMS OF THE ISSUE, INCLUDING THE MERITS AND RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

In accordance with the recommendation of Independent Directors of our Company, pursuant to their resolution dated September September 23, 2025, the above provided price band is justified based on quantitative factors/ KPIs disclosed in the "Basis for the Issue Price" section on page 143 of the RHP vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in the "Basis for the Issue Price" section beginning on the page 143 of the RHP and provided below in this advertisement.

Risk Factors

For details, refer to section titled *"Risk Factors"* on page 36 of the RHP.

1. **We have a low proposal-to-order conversion ratio of 10.24%, 8.98%, and 7.79% during Fiscals 2025, 2024, and 2023 respectively:** Our Company has received less than 11% of the total value of proposals submitted over the past three financial years. Since a substantial part of our business is project-based and non-recurring, we are heavily reliant on a continuous and effective lead generation and conversion process. The following table sets forth certain financial information in respect of the proposals submitted and concluded by our Company for the periods indicated:

Particulars	As of and for the years ended		
	March 31, 2025	March 31, 2024	March 31, 2023
Value of proposals submitted (₹ in lakhs)	4,64,950.00	4,49,109.19	3,71,059.98
Value of orders received (₹ in lakhs)	47,623.45	40,350.23	28,893.67
Proposal to order conversion ratio (in %)	10.24%	8.98%	7.79%

The table below shows our order book details as at Fiscals 2025, 2024 and 2023, respectively:

Particulars	Fiscal 2025	Fiscal 2024	Fiscal 2023
Total Order Booking (in ₹ lakhs)	76,173.60	61,306.41	42,464.62
New Order Booking (in ₹ lakhs)	47,623.45	40,350.23	28,893.67

2. **Risk Related to Realization of Order Book:** Our order book, which reflects unexecuted portions of signed contracts, may not accurately represent future revenues or profitability. Projects in the order book are subject to delays, modifications, or cancellations due to factors beyond our control - such as customer payment issues, scope changes, regulatory delays, and economic or geopolitical uncertainties. The following table summarizes our order book by division as at July 31, 2025 and as at the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023:

Particulars by Division	Outstanding as at July 31, 2025 (in ₹ lakhs)	Percentage of Total order book	Outstanding as at March 31, 2025 (in ₹ lakhs)	Percentage of Total order book	Outstanding as at March 31, 2024 (in ₹ lakhs)	Percentage of Total order book	Outstanding as at March 31, 2023 (in ₹ lakhs)	Percentage of Total order book
Turnkey services	83,035.66	91.81%	73,259.95	96.17%	57,260.50	93.40%	37,991.85	89.47%
Stand-alone services	7,406.21	8.19%	2,913.65	3.83%	4,045.91	6.60%	4,472.77	10.53%
Total	**90,441.87**	**100.00%**	**76,173.60**	**100.00%**	**61,306.41**	**100.00%**	**42,464.62**	**100.00%**

3. **Our receivables outstanding for more than six months accounted for 55.62%, 43.88%, and 48.80% of total receivables in fiscals 2025, 2024, and 2023, respectively.** Our business faces significant credit risk due to the long duration of projects and deferred payment structures, including retention clauses. A substantial portion of our receivables remains outstanding beyond the due date, which impacts liquidity and increases working capital needs. As of March 31, 2025, 55.62% of our total trade receivables were overdue by more than six months. While we conduct financial assessments of customers and secure payments through instruments like letters of credit, delays and defaults—such as a major write-off of ₹ 854.29 lakhs in FY2022—highlight ongoing collection risks. These delays may require legal action, damage client relationships, and adversely affect our cash flows, financial condition, and operational efficiency.

(₹ in lakhs)

Particulars	FY 2025	FY 2024	FY 2023
Amount Outstanding for more than 6 Months up to 1 year	4,747.97	457.88	831.43
% of Total Receivables	31.10%	4.55%	8.02%
Amount Outstanding for more than 1 year	3,742.44	3,958.52	4,227.18
% of Total Receivables	24.51%	39.33%	40.78%

4. **Our business is working capital intensive, with a net working capital requirement of ₹9,881.10 lakhs for fiscal 2025, representing 29.05% of the total assets:** Our business model is highly dependent on significant working capital for supplier advances, project mobilization, and issuance of bank guarantees. we intend to utilize ₹ 12,700.00 lakhs (as part of the Net Proceeds) towards funding our incremental working capital requirements in Fiscal 2026 and Fiscal 2027. Delays in client payments, retention of funds by customers, and projects with back-ended payment schedules strain our liquidity. As of March 31, 2025, our net working capital stood at ₹9,881.10 lakhs which is 29.05% of the total assets, with working capital days of 195, reflecting heavy reliance on internal accruals and borrowings.
5. **Our operating cash flows have been negative in Fiscals 2025 and 2023, amounting to ₹(3,614.48) lakhs and ₹(1,388.90) lakhs, respectively:** Our Company has experienced negative net cash flow in operating, investing and financing activities in the past, the details of which are provided below:

(₹ in lakhs)

Financial Years	Consolidated Cash flows from	Amount	Reasons for negative cash flow
2025	Operating Activities	(3614.48)	On account of fund blocked in working capital cycle.
	Investing Activities	(2,004.65)	On account of (i) Purchase of new property; and (ii) investment in subsidiaries and other entities.
2024	Financing Activities	(1,196.32)	On account of (i) repayment of cash credit and packaging credit facilities; (ii) payment of lease liabilities; and (iii) financial costs.
	Investing Activities	(3,000.37)	On account of investment in mutual funds and increase in goodwill on account of acquisition of Subsidiaries
2023	Operating Activities	(1,388.90)	On account of increase in working capital requirement and income tax payment.

Continued on next page...

...continued from previous page.

6. **Out of our total procurements, 25.68%, 34.89%, and 36.82% of equipment were procured through related entities in Fiscals 2025, 2024, and 2023, respectively:** Our Company follows a scalable, asset-light and less capital-intensive business model and procures a significant portion of its equipment and materials from Associate, Promoter Group entities, and Group Companies ("Related Entities"). This strategy allows us to control cost and quality, and to scale operations efficiently. However, it also creates a concentration risk and potential conflicts of interest. A break up of our procurement cost incurred towards purchase of equipment from our Related Entities and third party manufacturers and suppliers, and as a percentage of total procurement cost, during the period indicated below has been provided below:

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	Procurement Costs (₹ in lakhs)	% of total procurement costs	Procurement Costs (₹ in lakhs)	% of total procurement costs	Procurement Costs (₹ in lakhs)	% of total procurement cost
Expenditure incurred towards purchase of equipment through Related Entities	5,445.00	25.68	4,225.05	34.89%	3,769.04	36.82%
Expenditure incurred towards purchase of equipment through third party manufacturers and suppliers	15,755.10	74.32	7,884.66	65.11%	6,468.39	63.18%
Total procurement cost	**21,200.10**	**100.00%**	**12,109.71**	**100.00%**	**10,237.43**	**100.00%**

7. **Exposure to International Operations and Associated Risks:** Our international operations expose us to complex project management, legal, tax and economic risks, and exchange rate fluctuations. Our inability to successfully manage our geographically diverse operations could adversely affect our business and results of operations.

Below is the region wise bifurcation of revenue earned by our Company from our (standalone as well as turnkey and others) orders, during the periods indicated:

Regions	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	Revenue (₹ lakhs)	Percentage of Total Revenue (%)	Revenue (₹ lakhs)	Percentage of Total Revenue (%)	Revenue (₹ lakhs)	Percentage of Total Revenue (%)
Middle East and North African region (MENA)	3,159.16	9.67	8,514.08	37.65	7,267.08	37.50
Gulf Cooperation Council region (GCC)	16,252.21	49.75	7,208.56	31.88	7,821.10	40.36
Economic Cooperation Organization region (ECO)	5,914.41	18.11	5,874.13	25.98	2,426.71	12.52
Southern African Development Community region (SADAC)	2,399.67	7.35	623.62	2.76	89.23	0.46
Southeast Asian region (SEA)	4,672.11	14.30	371.12	1.64	1,313.56	6.78
EUROPE	262.68	0.80	22.12	0.10	454.73	2.35
AMERICA	6.61	0.02	-	-	7.34	0.04
Total	**32,666.85**	**100.00**	**22,613.63**	**100.00**	**19,379.75**	**100.00**

8. **Dependence on Turnkey Engineering Solutions:** Our Company derives the majority of its revenue and order book from turnkey engineering solutions. Any inability to secure new turnkey contracts or loss/termination of existing ones may have a material adverse effect on our business, results of operations, and financial condition. A break up of revenue from operations earned by our Company from turnkey engineering solutions (turnkey services) and standalone services during the preceding three Fiscals, as a percentage of our total revenue, has been provided below:

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	Revenue from operations (₹ lakhs)	Percentage of total revenue (%)*	Revenue from operations (₹ lakhs)	Percentage of total revenue (%)*	Revenue from operations (₹ lakhs)	Percentage of total revenue (%)*
Turnkey services	24,350.14	75.51	19,560.58	87.43	17,444.66	91.67
Standalone services	7,895.74	24.49	2,811.35	12.57	1,586.21	8.33
Total	**32.245.88**	**100.00**	**22,371.93**	**100.00**	**19,030.87**	**100.00**

**Total Revenue excludes export incentives, commission, sales, scrap and transportation charges.*

9. **High Dependency on a Limited Number of Projects:** Our Company derives a substantial portion of revenue from a limited number of large projects. This concentration poses a material risk, as the loss, delay, reduction in scope, or cancellation of even a few such projects could significantly impact our revenue, profitability, and financial condition. The table set forth below provides our consolidated revenue from operations from our top five, top ten and top twenty projects (based on the order value), and such revenue as a percentage of total revenue in the Fiscal 2025, Fiscal 2024 and Fiscal 2023:

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	(in ₹ lakhs)	% of total revenue	(in ₹ lakhs)	% of total revenue	(in ₹ lakhs)	% of total revenue
Top five Projects	18,314.42	56.06	14,284.52	63.17	14,530.00	74.98
Top ten Projects	24,078.64	73.71	19,086.76	84.40	17,067.27	88.07
Top twenty Projects	28,645.03	87.69	20,814.61	92.04	18,567.06	95.81

10. **Dependence on Third-Party Contractors:** We build pharmaceutical and healthcare capabilities in key emerging economies by offering comprehensive start-to-finish (turnkey) engineering solutions for pharmaceuticals, biotechnology, and healthcare industries. In order to execute our projects, we undertake installation of equipment and materials through third party contractors, to ensure timely execution of projects. Our projects are therefore dependent upon availability of third party contractors and timely, cost-effective and quality execution of projects by such contractors.

Our project erection and commissioning cost for the Fiscals ended March 31, 2025, 2024 and 2023, is as follows:

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	(in ₹ lakhs)	% of total expenditure	(in ₹ lakhs)	% of total expenditure	(in ₹ lakhs)	% of total expenditure
Project erection and commissioning expenses	2,240.03	7.63	1,504.33	7.68	1,788.78	10.18

11. The Price to Earnings (P/E) ratio based on the Diluted EPS for Fiscal 2025 at lower end of the Price Band is 12.62 times and at upper end of Price Band is 13.32 times.

Particulars	P/E at the lower end of the price band (no. of times)	P/E at the higher end of the price band (no. of times)
a) P/E ratio based on Basic EPS as at March 31, 2025	12.62	13.32
b) P/E ratio based on Diluted EPS as at March 31, 2025	12.62	13.32

12. Weighted average return on Net Worth for past financial years i.e. Fiscal 2025, Fiscal 2024 and Fiscal 2023, based on Restated Consolidated Financial Information is 24.37%.

13. **Weighted average cost of acquisition of all Equity Shares transacted in the 3 years, 18 months and 1 year preceding the date of the Red Herring Prospectus**

Period	WACA (INR)	Floor Price (₹ 181) is 'X' times the WACA	Cap Price (₹ 191) is 'X' times the WACA
For 3 years	88.83	2.04	2.15
Last 18 months	87.06	2.08	2.19
For 1 year	131.86	1.37	1.45

14. **Weighted average cost of acquisition ("WACA"), floor price and cap price**

Past Transactions	Weighted average cost of acquisition	Floor Price	Cap Price
	(₹)	₹181	₹191
WACA of Equity Shares that were issued by our Company	NA	NA	NA
WACA of Equity Shares that were acquired or sold by way of secondary transactions	NA	NA	NA
Since there were no primary or secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of this Red Herring Prospectus, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions where our Promoters/members of our Promoter Group or Shareholder(s) having the right to nominate director(s) on the Board of our Company, are a party to the transaction, during the three years prior to the date of filing of this Red Herring Prospectus irrespective of the size of the transaction, is as below:			
a) Based on primary issuances	5.30	34.15	36.04
b) Based on secondary transactions	988	0.18	0.19

15. The BRLM associated with the Issue has handled 27 public issues in the current financial year and preceding two financial years, out of which 5 issues closed below the offer price on the listing date.

Name of BRLM	Total Public Issues	Issued closed below the offer price on listing date
Unistone Capital Private Limited	27	5
Total	**27**	**5**

Continued on next page...

...continued from previous page.

Additional Information for Investors

1. Our Company has not undertaken pre-IPO placement and Promoter or members of Promoter Group have not undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the Company from the date of the Draft Red Herring Prospectus ("**DRHP**") till date.
2. The aggregate pre-Issue and post-Issue shareholding, of each of our Promoters, members of our Promoter Group and additional top 10 shareholders (apart from our Promoters) as on the date of this advertisement and post-Issue shareholding as at allotment is set forth below:

S. No.	Pre-Issue shareholding at the date of this Advertisement			Post-Issue shareholding as at the date of Allotment[1]			
				At the lower end of the price band (₹ 181)		At the upper end of the price band (₹ 191)	
	Name of the Shareholder	Number of Equity Shares	Shareholding (in %)	Number of Equity Shares	Shareholding (in %)	Number of Equity Shares	Shareholding (in %)
	Promoters						
1.	Aasif Ahsan Khan	1,84,56,779	56.98%	1,84,56,779	41.52%	1,84,56,779	41.52%
2.	Hemant Mohan Anavkar	38,08,761	11.76%	38,08,761	8.57%	38,08,761	8.57%
3.	Aarif Ahsan Khan	45,70,500	14.11%	45,70,500	10.28%	45,70,500	10.28%
4.	Manisha Hemant Anavkar	38,08,772	11.76%	38,08,772	8.57%	38,08,772	8.57%
	Total (A)	**3,06,44,812**	**94.61%**	**3,06,44,812**	**68.94%**	**3,06,44,812**	**68.94%**
	Promoter Group						
5.	Aatif Ahsan Khan	22	0.00%	22	0.00%	22	0.00%
	Total (B)	**22**	**0.00%**	**22**	**0.00%**	**22**	**0.00%**
	Total ((A)+(B))[2]	**3,06,44,834**	**94.61%**	**3,06,44,834**	**68.94%**	**3,06,44,834**	**68.94%**
	Additional top 10 Shareholders						
6.	Raj Narendra Mehta	3,34,004	1.03%	3,34,004	0.75%	3,34,004	0.75%
7.	Harshad Rasiklal Sheth	3,03,640	0.94%	3,03,640	0.68%	3,03,640	0.68%
8.	Saumya Ketan Kakrecha	3,03,640	0.94%	3,03,640	0.68%	3,03,640	0.68%
9.	Jitendra Vadilal Khandol	1,67,002	0.52%	1,67,002	0.38%	1,67,002	0.38%
10.	Niket Nilesh Shah	72,388	0.22%	72,388	0.16%	72,388	0.16%
11.	Maa Pahari Mercantiles Private Limited	55,671	0.17%	55,671	0.13%	55,671	0.13%
12.	Manish Kumar Jain	55,660	0.17%	55,660	0.13%	55,660	0.13%
13.	Parekh Dhruv Prakash	55,660	0.17%	55,660	0.13%	55,660	0.13%
14.	Thacker Minaxi Manilal	55,660	0.17%	55,660	0.13%	55,660	0.13%
15.	Dhawal Arvind Thakker	55,660	0.17%	55,660	0.13%	55,660	0.13%
	Total (C)	**14,58,985**	**4.50%**	**14,58,985**	**3.28%**	**14,58,985**	**3.28%**
	Total (A) + (B) + (C)	**3,21,03,819**	**99.11%**	**3,21,03,819**	**72.22%**	**3,21,03,819**	**72.22%**

[1] *Based on the Issue price of ₹ [●] and subject to finalisation of the basis of allotment.*

[2] *There are no primary or secondary transactions undertaken by promoter or promoter group from the date of Draft Red Herring Prospectus till date.*

BASIS FOR THE ISSUE PRICE

The Price Band and the Issue Price will be determined by our Company in consultation with the Book Running Lead Manager, and on the basis of assessment of market demand for the Equity Shares of face value of ₹ 10 each issued through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹ 10 each and the Floor Price is 18.1 times the face value and the Cap Price is 19.1 times the face value.

Bidders should read below mentioned information along with the *"Risk Factors"*, *"Our Business"*, *"Financial Statements"* and *"Management Discussion and Analysis of Financial Condition and Results of Operations"* on pages 36, 201, 304 and 368 of the RHP, respectively, to have an informed view before making an investment decision.

Qualitative Factors

Some of the qualitative factors which form the basis for computing the Issue Price are as follows:

1. A key turnkey engineering solution provider offering integrated engineering solutions with comprehensive service offerings.

We are a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. We provide comprehensive start to finish execution of controlled environment infrastructure with the ability to provide end to end solution encompassing designing, engineering, procurement, installation, testing, commissioning, management and operational support for a wide range of customers primarily in the pharmaceutical, biotechnological, and healthcare sectors across geographies.

2. Track record of executing projects across all dosage forms

Our company specializes in building pharmaceutical, biotech, and healthcare capabilities by providing end-to-end solutions that include design, engineering, procurement, installation, and testing of pharmaceutical equipment. We cover the entire project lifecycle and focus on three key elements: bio air, clean water, and process. With a strong track record in executing projects for various dosage forms—such as tablets, capsules, liquids, injectables, and semisolids—we cater to a wide range of products from oncology drugs to over-the-counter medications. Our experienced team excels in managing complex projects, ensuring quality and precision while leveraging our industry expertise to address the unique challenges of the pharmaceutical and healthcare sectors.

3. In-house software technology capabilities

Our promoters and key management have extensive experience in pharmaceutical engineering projects, enabling them to tackle challenges and boost productivity effectively. Our company has developed an in-house software called FabAssure, which tracks every project stage and helps teams coordinate their tasks on time. This system allows for real-time monitoring and encourages customer involvement, building trust and strong relationships. FabAssure connects local actions to project deadlines and uses a project management office (PMO) to resolve issues quickly, escalating any unresolved problems to senior management. This technology has shifted our execution methods from traditional to modern, automated approaches, improving efficiency, service quality, and operational control.

4. Asset-light and integrated business model

We use a scalable, asset-light business model by sourcing equipment from related entities and third-party suppliers, which eliminates the need for heavy capital investments in manufacturing. This approach allows us to focus on project execution and sales while ensuring timely delivery of high-quality equipment. By partnering with various equipment manufacturers, we can adjust our resources based on project needs, achieving cost savings and economies of scale. Our integrated model includes in-house teams for design, procurement, quality control, logistics, and project execution, reducing reliance on third-party suppliers and minimizing risks. This setup gives us a competitive edge over other providers that require larger investments and offer fewer services.

5. Diversified Order Book across geographies, clients, and business verticals

In the past three years, we have expanded our order book from ₹42,464.62 lakhs as of March 31, 2023, to ₹61,306.41 lakhs as of March 31, 2024, and ₹76,173.60 lakhs as of March 31, 2025. Our diverse expertise allows us to handle a wide range of projects, including granulation solutions, isolator containment systems, injectable projects, water treatment solutions, and cleanroom infrastructure development. We also execute pharmaceutical projects across all dosage forms, such as tablets, capsules, liquids, and semisolids.

6. Project execution across diverse and challenging geographies

We consolidate technical expertise and infrastructure for aseptic manufacturing and research in the pharmaceutical, healthcare, and biotech sectors across emerging economies. Our international operations enable us to deliver projects despite regional conflicts, supply chain disruptions, and recruitment challenges. Through thorough risk assessment and planning, we anticipate obstacles like regulatory and infrastructure issues and use local knowledge to ensure smooth execution. Leveraging our local presence, we navigate complexities, optimize procurement, and make informed decisions that enhance project profitability and sustainability.

7. Efficient lead funneling leading to higher mandate conversion

We provide turnkey engineering solutions to build pharmaceutical, biotech, and healthcare capabilities, focusing on projects that require significant capital investment and long-term financial commitment. Due to the complexity and technical nature of our projects, the process from lead generation to order confirmation involves extensive risk analysis, technical evaluation, and competitive bidding, often resulting in longer timelines. To maintain and grow our order book, our sales and marketing teams actively funnel leads from various sources and validate them through client interactions. These efforts, led by senior management, ensure steady project acquisition across multiple geographies.

8. Experienced Leadership Team with Fabtech Group parentage

We are part of the Fabtech Group, which has over two decades of experience in India and internationally, known for providing trusted turnkey engineering solutions. Following a 2020 demerger, the export division of FTIPL was transferred to our company, bringing with it ongoing orders, assets, and employees. Our promoters, Aasif Ahsan Khan, Hemant Mohan Anavkar, and Aarif Ahsan Khan, have more than three decades of combined experience in pharmaceutical engineering, playing key roles in our success. Led by CEO Ashwani Kumar Singh, who has over three decades of experience in the industry, our leadership team drives innovation and guides our growth in the pharmaceutical, biotech, and healthcare sectors.

For further details, see *"Risk Factors"* and *"Our Business"* on pages 36 and 201 of the RHP, respectively.

Quantitative Factors

The information presented in this section is derived from our Restated Consolidated Financial Statements. For details, see *"Financial Statements"* on page 304 of the RHP. Investors should evaluate our Company and form their decisions taking into consideration its earnings and based on its growth strategy. Some of the quantitative factors which may form the basis for computing the Issue price are as follows:

1. Basic and Diluted Earnings per Share (EPS), as adjusted for changes in capital.

Year ended	Basic EPS (in ₹)	Diluted EPS (in ₹)	Weight
Fiscal 2025	14.34	14.34	3
Fiscal 2024	8.43	8.43	2
Fiscal 2023	6.74	6.74	1
Weighted Average	**11.11**	**11.11**	-

Notes:

a) As derived from the Restated Consolidated Financial Statement of our Company.

b) Basic and Diluted Earnings per Share (₹) = Profit after tax excluding exceptional items before other comprehensive income attributable to equity shareholders for the year divided by the weighted average no. of equity shares of face value ₹ 10 each. The weighted average number of Equity Shares outstanding during the year is adjusted for bonus issue of Equity Shares.

c) Basic EPS and diluted EPS calculations are in accordance with Indian Accounting Standard 33 'Earnings per Share'.

d) Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights, i.e. (EPS x weight) for each year divided by the total of weights.

2. Price / Earning (P/E) Ratio in relation to Price band of ₹ 181 to ₹ 191 per Equity Share

Particulars	P/E at the lower end of the price band (no. of times)	P/E at the higher end of the price band (no. of times)
a) P/E ratio based on Basic EPS as at March 31, 2025	12.62	13.32
b) P/E ratio based on Diluted EPS as at March 31, 2025	12.62	13.32

Industry Price / Earning (P/E) Ratio

There are no listed companies in India that are of comparable size, from the same industry and with similar business model as that of our Company. Our Company is engaged in the business of building pharmaceutical, biotech and healthcare capabilities by offering comprehensive start to finish solutions in respect of select pharmaceutical equipment for a wide range of customers. In order to offer turnkey engineering solutions, we have adopted an export-focused asset-light approach which involves procurement of equipment from related entities, and offering comprehensive start-to-finish solutions encompassing designing, engineering, procurement, installation, and testing of select pharmaceutical equipment for a diverse customer base, with a focus on executing projects in emerging economies. Since, there are no listed companies in India operating a similar business model, as that of our Company, as on date of this Red Herring Prospectus, we do not have a listed industry peer.

3. Return on Net Worth (RONW):

Year ended	RoNW (%)	Weight
Fiscal 2025	26.83%	3
Fiscal 2024	20.64%	2
Fiscal 2023	24.43%	1
Weighted Average	**24.37%**	-

Notes:

a) As derived from the Restated Consolidated Financial Statement of our Company.

b) RoNW is calculated as net profit after taxation and other comprehensive income attributable to the equity shareholders of the Company divided by shareholders' funds for that year. Shareholders' funds = Share capital + reserves & surplus – revaluation reserves.

c) Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year / Total of weights.

4. Net Asset Value (NAV) per Equity Share

Financial Year	Net Asset Value per equity shares
As of March 31, 2025	53.44
After Completion of the Issue	
- At the Floor Price	88.05
- At the Cap Price	90.76
Issue Price	[●]

Notes:

a) Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of Equity shares outstanding during the year is adjusted for bonus issue of Equity shares. Net worth represents the aggregate value of equity share capital and other equity and are based on Restated Consolidated Financial Statement.

5. Comparison with listed industry peer:

There are no listed companies in India that are of comparable size, from the same industry and with similar business model as that of our Company. Our Company is engaged in the business of building pharmaceutical, biotech and healthcare capabilities by offering comprehensive start to finish solutions in respect of select pharmaceutical equipment for a wide range of customers. In order to offer turnkey engineering solutions, we have adopted an export-focused asset-light approach which involves procurement of equipment from related entities, and offering comprehensive start-to-finish solutions encompassing designing, engineering, procurement, installation, and testing of select pharmaceutical equipment for a diverse customer base, with a focus on executing projects in emerging economies. Since, there are no listed companies in India operating a similar business model, as that of our Company, as on date of this Red Herring Prospectus, we do not have a listed industry peer.

6. Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been used historically by our Company to understand and analyse the business performance, which in result, help us in analysing the growth of various verticals.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Issue Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations.

KPI	Explanations
Revenue from Operations (₹ Lakhs)	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps assess the overall financial performance of our Company and size of our business.
Total Income	Total income is used to track the total revenue generated by the business including other income.
EBITDA (₹ Lakhs)	EBITDA provides information regarding the operational efficiency of the business.
EBITDA Margin (%)	EBITDA Margin is an indicator of the operational profitability and financial performance of our business.
Profit After Tax (₹ Lakhs)	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin	PAT Margin is an indicator of the overall profitability and financial performance of our business.
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders' funds.
Debt To Equity Ratio	Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage.
Interest Coverage Ratio	The interest coverage ratio is a debt and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Return on Capital Employed	ROCE provides how efficiently our Company generates earnings from the capital employed in the business.
Current Ratio	It tells management how business can maximize the current assets on its balance sheet to satisfy its current debt and other payables.
Offer Submission (In Lakhs)	Offer Submission means value of proposal submitted to customers against leads and customer enquiries.
Order Booking	Order Booking means customer orders which are awarded to our Company.
Revenue (Other than export incentives)	Revenue (Other than export incentives) means revenue from operations other than export incentives or other operating income.
Proposal to order conversion ratio (in %)	Proposal to order conversion ratio is calculated by dividing the order booking with offer submission.
Book to bill ratio	Book to bill ratio is calculated by dividing order booked with revenue other than export incentive.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated September 11, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of this RHP. Further, the KPIs herein have been certified by M/s. Ajmera & Ajmera Chartered Accountants, by their certificate dated September 22, 2025.

Financial KPI of our Company

Sr No.	Metric	Unit	As of and for the Fiscal		
			2025	2024	2023
1	Revenue From operations	₹ in Lakhs	32,666.85	22,613.63	19,379.75
2	Total Income	₹ in Lakhs	33,594.21	23,060.44	19,991.01
3	EBITDA	₹ in Lakhs	4,727.91	3,975.11	3,237.68
4	EBITDA Margin	(%)	14.07%	17.24%	16.20%
5	Profit/(loss) after tax for the year/ period	₹ in Lakhs	4,645.30	2,721.74	2,173.37
6	Net profit Ratio/ Margin	(%)	13.83%	11.80%	10.87%
7	Return on Equity (ROE)	(%)	30.46%	24.65%	27.80%
8	Debt To Equity Ratio	Multiple	0.32	0.07	0.39
9	Interest Coverage Ratio	Multiple	21.41	19.83	11.83
10	ROCE	(%)	24.46%	28.76%	29.35%
11	Current Ratio	Multiple	1.37	1.70	1.48

Notes:

a) As certified by M/s. Ajmera & Ajmera, Chartered Accountants pursuant to their certificate dated September 22, 2025. The Audit committee in its resolution dated September 11, 2025 has confirmed that the Company has not disclosed any KPIs to any investors at any point of time during the three years preceding the date of this Red Herring Prospectus other than as disclosed in this section.

b) Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.

c) EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items.

d) EBITDA Margin refers to EBITDA during a given period as a percentage of total income during that period.

e) Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes by our total income.

f) Return on equity (RoE) is equal to profit for the year divided by the average total equity and is expressed as a percentage.

g) Debt to equity ratio is calculated by dividing the debt (i.e., borrowings (current and non-current) and current maturities of long-term borrowings) by total equity (which includes issued capital and all other equity reserves and NCI).

h) Interest Coverage Ratio measures our ability to make interest payments from available earnings and is calculated by dividing EBIT by finance cost. EBIT refers to earnings before interest, taxes, gain or loss from discontinued operations and exceptional items.

i) RoCE (Return on Capital Employed) (%) is calculated as EBIT divided by average capital employed. Capital employed is calculated as net worth and total debt less net deferred tax assets.

j) Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.

See *"Management Discussion and Analysis of Financial Position and Results of Operations"* on page 368 of the RHP for the reconciliation and the manner of calculation of our key financial performance indicators.

Further, set forth below are some of our key operational performance indicators as of and for the periods indicated which have been approved our Audit Committee pursuant to its resolution dated September 11, 2025.

Operational KPIs for the Company

Sr No.	Metric	Unit	As of and for the Fiscal		
			2025	2024	2023
1	Offer Submission	₹ In Lakhs	4,64,950.00	4,49,109.19	3,71,059.98
2	Order Booking	₹ In Lakhs	47,623.45	40,350.23	28,893.67
3	Proposal to order conversion ratio	(%)	10.24%	8.98%	7.79%
4	Book to bill ratio	Multiple	1.48	1.80	1.52
5	Revenue (Other than export incentives)	₹ In Lakhs	32,245.88	22,433.50	19,033.41

Note:

a) Offer Submission means value of proposal submitted to customers against leads and customer enquiries.

b) Order Booking means customer orders which are awarded to our Company.

c) Proposal to order conversion ratio is calculated by dividing the order booking with offer submission.

d) Book to bill ratio is calculated by dividing order booked with revenue other than export incentive.

e) Revenue (Other than export incentives) means revenue from operations other than export incentives or other operating income.

For further information in relation to historical use of such KPIs by our Company to monitor the operational and/or financial performance of our Company, *"Our Business—Key Performance Indicators"* on pages 205 of the RHP.

7. Weighted average cost of acquisition ("WACA"), floor price and cap price

a) Price per share of the Company based on primary issuances of Equity Shares or convertible securities (excluding issuance of Equity Shares under ESOS or pursuant to a bonus issue) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-transaction capital before such transactions)in a single transaction or multiple transactions combined together over a span of rolling 30 days.

There have been no primary issuances of Equity Shares or convertible securities (excluding issuance of Equity Shares under ESOS or pursuant to a bonus issue) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-transaction capital before such transactions)in a single transaction or multiple transactions combined together over a span of rolling 30 days.

b) Price per share of the Company based on secondary sale or acquisition of Equity Shares or convertible securities (excluding gifts) involving any of the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) in the Board of Directors of the Company are a party to the transaction, during the 18 months preceding the date of filing of the Red Herring Prospectus, where the acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-transaction capital before such transactions), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

There have been no secondary sales/transfers or acquisitions of any Equity Shares or convertible securities (excluding gifts) where the Promoters, members of the Promoter Group, the Promoter or Shareholder(s) having the right to nominate director(s) in the Board of Directors of the Company are a party to the transaction, during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-offer capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Since there are no transactions to report to under (a) and (b) therefore, information based on last five primary or secondary transactions (secondary transactions where our Promoters/ members of our Promoter Group or Shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), during the three years prior to the date of this Draft Red Herring Prospectus irrespective of the size of transactions, is as below:

Primary transactions:

Date of allotment	No. of equity shares allotted	Face value per equity share (₹)	Issue price per equity share (₹)	Nature of allotment	Nature of consideration	Total Consideration (in₹ Lakhs)
January 03, 2024	1,58,854	10	988	Private Placement	Cash	1,569.48
April 03, 2024	2,94,47,490	10	NA	Bonus issue in the ratio of ten (10) bonus equity shares for every one (01) existing Equity Share held on March 31, 2024	Consideration other than Cash	NA
Weighted average cost of acquisition (WACA)						**5.30**

Secondary transactions:

Date of transfer of Equity Shares	Number of Equity Shares transferred	Details of transferor (s)	Details of transferee (s)	Face value per equity share (₹)	Issue price per equity share (₹)	Nature of allotment	Nature of consid-eration	Total Consideration (in ₹ Lakhs)
January 03, 2024	1	T Square Enterprises Pvt Ltd	Manisha Anavkar	10	988	Transfer	Cash	0.01
February 05, 2024	1	Haifa Aasif Khan	Manisha Anavkar	10	988	Transfer	Cash	0.01
March 30, 2024	15,890	Acaccia International TR LLC	Aasif Khan	10	988	Transfer	Cash	156.99
Weighted average cost of acquisition (WACA)								**988**

Floor price and cap price being 34.15 and 36.04 times respectively of the weighted average cost of acquisition (WACA) based on primary and 0.18 and 0.19 times respectively of the weighted average cost of acquisition (WACA) based on secondary transaction(s) as disclosed in the above table, shall be disclosed in the following manner:

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price ₹181	Cap Price ₹191
WACA of Equity Shares that were issued by our Company	NA	NA	NA
WACA of Equity Shares that were acquired or sold by way of secondary transactions	NA	NA	NA
Since there were no primary or secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Red Herring Prospectus, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions where our Promoters/members of our Promoter Group or Shareholder(s) having the right to nominate director(s) on the Board of our Company, are a party to the transaction, during the three years prior to the date of filing of the Red Herring Prospectus irrespective of the size of the transaction, is as below:			
a) Based on primary issuances	5.30	34.15	36.04
b) Based on secondary transactions	988	0.18	0.19

c) Justification for Basis for Issue Price.

Explanation for Issue Price / Cap Price being [●] times of weighted average cost of acquisition of primary issuance price / secondary transaction price of Equity Shares along with our Company's key performance indicators and the Fiscals 2025, 2024 and 2023.

1. A key turnkey engineering solution provider offering integrated engineering solutions with comprehensive service offerings.
2. Track record of executing projects across all dosage forms.
3. In-house software technology capabilities.
4. Asset-light and integrated business model.
5. Diversified Order Book across geographies, clients, and business verticals.
6. Project execution across diverse and challenging geographies.
7. Efficient lead funneling leading to higher mandate conversion.
8. Experienced Leadership Team with Fabtech Group parentage.

d) The Issue Price is [●] times of the Face Value of the Equity Shares.

The Issue Price of ₹ [●] has been determined by our Company in consultation with the BRLM, on the basis of market demand from investors for Equity Shares, as determined through the Book Building Process, and is justified in view of the above qualitative and quantitative parameters. Investors should read the above-mentioned information along with *"Risk Factors"*, *"Our Business"*, *"Management Discussion and Analysis of Financial Position and Results of Operations"* and *"Financial Statements"* on pages 36, 201, 368 and 304 of the RHP, respectively, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the *"Risk Factors"* and you may lose all or part of your investments.

For further details, please see the chapter titled "BASIS FOR ISSUE PRICE" beginning on page 143 of the RHP. Please refer to the website of the BRLM: www.unistonecapital.com. You may scan the QR code for accessing the website of Unistone Capital Private Limited.

Continued on next page...

...continued from previous page.

AN INDICATIVE TIMETABLE IN RESPECT OF THE ISSUE IS SET OUT BELOW:

Submission of Bids (other than Bids from Anchor Investors):

Bid/ Issue Period (except the Bid/ Issue Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. Indian Standard Time ("**IST**")
Bid/ Issue Closing Date*	
Submission of Electronic Applications (Online ASBA through 3-in-1 accounts) - For RIBs, other than QIBs , Non-Institutional Investors and Eligible Employees Bidding in the Employee Reservation Portion	Only between 10.00 a.m. and up to 5.00 p.m. IST
Submission of Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA applications where Bid Amount is up to ₹500,000)	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Syndicate Non-Retail, Non-Individual Applications)	Only between 10.00 a.m. and up to 3.00 p.m. IST
Submission of Physical Applications (Bank ASBA)	Only between 10.00 a.m. and up to 1.00 p.m. IST
Submission of Physical Applications (Syndicate Non-Retail, Non-Individual Applications where Bid Amount is more than ₹500,000)	Only between 10.00 a.m. and up to 12.00 p.m. IST
Modification/ Revision/cancellation of Bids	
Upward Revision of Bids by QIBs and Non-Institutional Bidders categories#	Only between 10.00 a.m. and up to 5.00 p.m. IST on Bid/ Offer Closing Date
Upward or downward Revision of Bids or cancellation of Bids by RIBs and Eligible Employees Bidding in the Employee Reservation Portion	Only between 10.00 a.m. and up to 5.00 p.m. IST on Bid/Issue Closing Date

** UPI mandate end time and date shall be at 05:00 p.m. on Bid/ Issue Closing Date.*

 # QIBs and Non-Institutional Bidders can neither revise their bids downwards nor cancel/withdraw their bids.

On the Bid/ Issue Closing Date, the Bids shall be uploaded until:

(i) 4.00 p.m. IST in case of Bids by QIBs and Non-Institutional Bidders, and

(ii) until 5.00 p.m. IST or such extended time as permitted by the Stock Exchanges, in case of Bids by RIBs.

On Bid/Issue Closing Date, extension of time may be granted by Stock Exchanges only for uploading Bids received RIBs, after taking into account the total number of Bids received and as reported by the BRLMs to the Stock Exchanges.

Bid / Issue Programme:

Event	Indicative Date
Bid/ Issue Closing Date	Wednesday, October 1, 2025
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about Friday, October 3, 2025
Initiation of refunds (if any, for Anchor Investors) / unblocking of funds from ASBA Account*	On or about Monday, October 6, 2025
Credit of the Equity Shares to depository accounts of Allottees	On or about Monday, October 6, 2025
Commencement of trading of the Equity Shares on the Stock Exchanges	On or about Tuesday, October 7, 2025

** In case of (i) any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding three Working Days from the Bid/Issue Closing Date for cancelled / withdrawn / deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ withdrawal/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked (ii) any blocking of multiple amounts for the same ASBA Form (for amounts blocked through the UPI Mechanism), the Bidder shall be compensated at a uniform rate ₹ 100 per day or 15% per annum of the total cumulative blocked amount except the original application amount, whichever is higher from the date on which such multiple amounts were blocked till the date of actual unblock; (iii) any blocking of amounts more than the Bid Amount, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the difference in amount, whichever is higher from the date on which such excess amounts were blocked till the date of actual unblock; (iv) any delay in unblocking of non-allotted/ partially allotted Bids, exceeding three Working Days from the Bid/Issue Closing Date, the Bidder shall be compensated at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher for the entire duration of delay exceeding three Working Days from the Bid/Issue Closing Date by the SCSB responsible for causing such delay in unblocking. The BRLM shall be liable for compensating the Bidder at a uniform rate of ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher from the date of receipt of the investor grievance until the date on which the blocked amounts are unblocked. Further, Bidders shall be entitled to compensation in the manner prescribed by SEBI and any other applicable law in case of delays in resolving investor grievances in relation to blocking/unblocking of funds. Further, in terms of circulars prescribed by SEBI from time to time, the payment of processing fees to the SCSBs shall be undertaken pursuant to an application made by the SCSBs to the BRLM. and such application shall be made only after (i) unblocking of application amounts for each application received by the SCSB has been fully completed, and (ii) applicable compensation relating to investor complaints has been paid by the SCSB. The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022.*

ASBA* | **Simple, Safe, Smart way of Application!!!**

*Applications Supported by Blocked Amount ("**ASBA**") is a better way of applying to offers by simply blocking the fund in the bank account. For further details, check section on ASBA.

Mandatory in public issues.
No cheque will be accepted.

UPI — UNIFIED PAYMENTS INTERFACE

UPI-Now available in ASBA for Retail Individual Investors and Non Institutional Investor applying in public issues where the application amount is up to ₹ 500,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. Retail Individual Investors and Non-Institutional Investors also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 read with press release dated September 17, 2021, CBDT Circular No. 3 of 2023 dated March 28, 2023.

*ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by (i) Retail Individual Investors in the Retail Category; (ii) Non-Institutional Investors with an application size of up to ₹ 500,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in the Bid Cum Application Form and abridged prospectus and also please refer to the section "Issue Procedure" on page 444 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("**AIBI**") and Stock Exchanges and in the General Information Document. The Bid Cum Application Form and the Abridged Prospectus can be downloaded from the websites of BSE Limited ("**BSE**") and National Stock Exchange of India Limited ("**NSE**", and together with BSE, the "**Stock Exchanges**") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes &intmId=43, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. ICICI Bank Limited has been appointed as the Sponsor Bank for the Issue, in accordance with the requirements of SEBI circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail Id: ipo.upi@npci.org.in.*

In case of any revision to the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, in consultation with Book Running Lead Manager, for reasons to be recorded in writing, extend the Bid / Issue Period for a minimum period of one (1) Working Day, subject to the Bid/ Issue Period not exceeding a total of 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Manager and at the terminals of the Syndicate Member(s) and by intimation to the Designated Intermediaries and the Sponsor Banks.

This is an Issue in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("**SCRR**"), read with Regulation 31 of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "**SEBI ICDR Regulations**"). The Issue is being made through the Book Building Process in terms of Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**") (the "**QIB Portion**"), provided that our Company, in consultation with the BRLM, may allocate up to 60% of the QIB Portion to Anchor Investors, and the basis of such allocation will be on a discretionary basis by our Company, in consultation with the BRLM, in accordance with the SEBI ICDR Regulations (the "**Anchor Investor Portion**"), out of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("**Anchor Investor Allocation Price**"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the "**Net QIB Portion**"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15% of the Net Issue shall be available for allocation to NIIs ("**Non-Institutional Category**") of which one-third of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹2.00 lakhs and up to ₹10.00 lakhs and two-thirds of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹10.00 lakhs and under-subscription in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, not less than 35% of the Net Issue shall be available for allocation to RIIs ("**Retail Category**"), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Issue Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Issue only through the Application Supported by Blocked Amount ("**ASBA**") process and shall provide details of their respective bank account (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter), if applicable, in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or by Sponsor Bank(s) under the UPI Mechanism, as applicable to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see *"Issue Procedure"* on page 444 of this Red Herring Prospectus.

Bidders/Applicants should ensure that DP ID, PAN and the Client ID and UPI ID (for UPI Bidders bidding through UPI Mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID and UPI ID available (for UPI Bidders bidding through the UPI Mechanism) in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for UPI Bidders bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk.

Investors must ensure that their PAN is linked with Aadhaar and are in compliance with the notification issued by Central Board of Direct Taxes notification dated February 13, 2020 and read with press releases dated June 25, 2021, September 17, 2021 and March 28, 2023 and any subsequent press releases in this regard.

Contents of the Memorandum of Association of our Company as Regards its Objects: For information on the main objects of our Company, please see *"History and Certain Corporate Matters - Main objects of our Company"* on page 250 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see *"Material Contracts and Documents for Inspection"* on page 508 of the RHP.

Liability of the Members of our Company: Limited by shares.

Amount of Share Capital of our Company and Capital Structure: As on the date of the RHP, the authorised share capital of our Company is ₹4,500.00 lakhs divided into 4,50,00,000 Equity Shares of face value of ₹10 each. The issued, subscribed and paid-up Equity share capital of our Company is ₹3,239.22 lakhs divided into 3,23,92,239 Equity Shares of face value of ₹10 each. For details of the capital structure of the Company, see *"Capital Structure"* beginning on page 117 of the RHP.

Names of the Initial Signatories to the Memorandum of Association of the Company and the Number of Equity Shares Subscribed by them: The initial signatories of the Memorandum of Association of the Company are Manisha Sanjay Dhumal and Sanjay Tulshiram Dhumal. For details of the share capital history of our Company please see *"Capital Structure"* beginning on page 117 of the RHP.

Listing: The Equity Shares, once issued through the Red Herring Prospectus, are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from the BSE and the NSE for listing the Equity Shares pursuant to letters each dated December 2, 2024, respectively. For the purposes of the Issue, the Designated Stock Exchange shall be NSE. A copy of the Red Herring Prospectus and the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For further details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus until the Bid/ Issue Closing Date, see *"Material Contracts and Documents for Inspection"* on page 508 of the RHP.

Disclaimer Clause of Securities and Exchange Board of India ("SEBI"): SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities stated in the Offer Documents. The investors are advised to refer to page 424 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the RHP has been cleared or approved by BSE Limited nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to the page 426 of the RHP for the full text of the disclaimer clause of BSE.

Disclaimer Clause of NSE (the Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Issue Document. The investors are advised to refer to page 426 of the RHP for the full text of the disclaimer clause of NSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to *"Risk Factors"* on page 36 of the RHP.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
UNISTONE **Unistone Capital Private Limited** A/ 305, Dynasty Business Park, Andheri-Kurla Road, Andheri East, Mumbai – 400 059, Maharashtra, India. **Telephone:** +91 224 604 6494; **Facsimile:** N.A.; **Email:** mb@unistonecapital.com **Website:** www.unistonecapital.com; **Investor grievance email:** compliance@unistonecapital.com **Contact Person:** Brijesh Parekh; **SEBI registration number:** INM000012449 **CIN:** U65999MH2019PTC330850	**Bigshare Services Private Limited** S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Center, Mahakali Caves Road, Andheri East, Mumbai-400 093, Maharashtra, India. **Telephone:** +91 226 263 8200; **Facsimile:** N.A.; **Email:** ipo@bigshareonline.com **Website:** https://www.bigshareonline.com; **Investor grievance email:** investor@bigshareonline.com **Contact Person:** Vinayak Morbale; **SEBI registration number:** INR000001385; **CIN:** U99999MH1994PTC076534	**Neetu Sunil Buchasia** **FABTECH TECHNOLOGIES LIMITED** 1st Floor ABR Emerald, Plot No D8, Street 16, MIDC Andheri East, Chakala MIDC, Mumbai – 400 093, Maharashtra, India. **Telephone:** +91 226 554 0300; **Facsimile:** N.A.; **E-mail:** cs@fabtechnologies.com **Website:** www.fabtechnologies.com Investors can contact the Company Secretary and Compliance Officer, the Book Running Lead Manager or the Registrar to the Issue in case of any pre-Issue or post-Issue related grievances, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc.

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the *"Risk Factors"* beginning on page 36 of the RHP before applying in the Issue. A copy of the RHP will be made available on the website of SEBI at www.sebi.gov.in and is available on the websites of the BRLM, Unistone Capital Private Limited at www.unistonecapital.com and at the website of the Company, FABTECH TECHNOLOGIES LIMITED at www.fabtechnologies.com and the websites of the Stock Exchanges, for BSE at www.bseindia.com and for National Stock Exchange of India Limited at www.nseindia.com.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the Abridged Prospectus shall be available on the website of the Company, the BRLM and the Registrar to the Issue at: www.fabtechnologies.com, www.unistonecapital.com and https://www.bigshareonline.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORM: Bid cum Application Form can be obtained from the Registered Office of our Company, **FABTECH TECHNOLOGIES LIMITED:** Telephone: +91 226 159 2900; **BRLM:** Unistone Capital Private Limited, Tel: +91 022 46046494 and **Syndicate Members:** Globalworth Securities Limited, Telephone: +91 222 919 0011, Registered Brokers, SCSBs, Designated RTA Locations and Designated CDP Locations for participating in the Issue. Bid cum Application Forms will also be available on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com and at all the Designated Branches of SCSBs, the list of which is available on the websites of the Stock Exchanges and SEBI.

SUB-SYNDICATE MEMBERS: Kotak Securities Limited; HDFC Securities Limited; Axis Securities Limited; ICICI Securities Limited; JM Financial Services Limited; Prabhudas Lilladher Pvt Ltd; Nuvama Wealth and Investment Limited; Yes Securities (India) Limited; IIFL Securities Limited; SBI Capital Securities Limited; Motilal Oswal Securities Limited; LKP Securities Limited.

ESCROW COLLECTION BANK(S)/ PUBLIC ISSUE BANK(S)/ REFUND BANK(S)/ SPONSOR BANKS: ICICI Bank Limited.

UPI: UPI Bidders can also Bid through UPI Mechanism.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For **FABTECH TECHNOLOGIES LIMITED**
On behalf of the Board of Directors
Sd/-
Neetu Sunil Buchasia
Company Secretary and Compliance Officer

Place: Mumbai
Date: September 23, 2025

FABTECH TECHNOLOGIES LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed a red herring prospectus dated September 22, 2025 with the RoC. The RHP is made available on the website of the SEBI at www.sebi.gov.in as well as on the website of the BRLM i.e., Unistone Capital Private Limited at www.unistonecapital.com, the website of the NSE at www.nseindia.com and the website of the BSE at www.bseindia.com and the website of the Company at www.fabtechnologies.com. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section *"Risk Factors"* beginning on page 36 of the RHP. Potential investors should not rely on the DRHP for making any investment decision but should only rely on the information included in the RHP filed by the Company with the RoC.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction, including India. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. There will be no public offering of Equity Shares in the Unites States.

CONCEPT

INVENT ASSETS SECURITISATION & RECONSTRUCTION PRIVATE LIMITED invent

Regd. Office : Bakhtawar, Suite 'B', Ground Floor, Backbay Reclamation Scheme Block III, 229, Nariman Point, Mumbai - 400021.

POSSESSION NOTICE

Whereas, the undersigned being the Authorised Officer of **Invent Assets Securitisation & Reconstruction Pvt. Ltd. ("INVENT")** under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (54 of 2002) (the Act) and in exercise of powers conferred under section 13(2) read with (Rule 3) of the Security Interest (Enforcement) Rules, 2002 issued a Demand Notice dated **April 30, 2025** acting in its capacity as Trustee of INVENT/1516/S55 Trust & INVENT/1516/S52 Trust calling upon the Guarantor's / Mortgagor's of **M/s. Aakash Tiles Private Limited** (under liquidation) ("Borrower") as specified therein **Mr. Piyush Mathur** and **Mrs. Shalini Mathur,** jointly and severally to repay the amount mentioned in the notice being **Rs. 3,80,94,68,001.45 /- (Rupees Three Hundred Eighty Crores Ninety-Four Lakhs Sixty-Eight Thousand One Rupee and Forty-Five Paise only)** respectively as on 31.01.2025 along with further interest, expenses and other charges payable thereon is due and payable by you within 60 days from the date of receipt of the said notice.

The Borrower along with its co-borrowers and/or mortgagors Mr. Piyush Mathur and Mrs. Shalini Mathur having failed to repay the amount, notice is hereby given to them and the public in general that INVENT acting in its capacity as a trustee of INVENT/1516/S52 Trust & INVENT/1516/S55 Trust and on behalf of consortium of Banks has taken possession of the property described herein below in exercise of powers conferred on him/her under section 13(4) of the read with rule 8 Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 on **19th day of September of the year 2025 at 1.45 p.m.**

The Borrower, co-borrowers and/or mortgagors and/or guarantors in particular and the public in general is hereby cautioned not to deal with the property in any manner and any dealings with the property, if any will be subject to the charge of Invent Assets Securitisation & Reconstruction Pvt. Ltd. for an amount of **Rs. 3,80,94,68,001.45 /- (Rupees Three Hundred Eighty Crores Ninety-Four Lakhs Sixty-Eight Thousand One Rupee and Forty-Five Paise only)** as on **31.01.2025** along with further interest, expenses and other charges payable thereon.

The Borrower, co-borrowers and/or mortgagors and/or guarantors attention is invited to provision of sub section (8) of section 13 of the Act, in respect of time available, to redeem the secured assets.

DESCRIPTION OF PROPERTY

A-9/A-10, "Kanishka Co-Op. Housing Society Limited", 2nd Floor, MIDC, Dombivali (East), Mumbai - 421203.

Date : September 24, 2025 **Sd/-**

Madhurii Dadarkar, Authorised Officer
Invent Assets Securitisation & Reconstruction Pvt. Ltd.
(acting in capacity as Trustee of the INVENT/1516/S55 Trust & INVENT/1516/S52 Trust)

GODFREY PHILLIPS INDIA LIMITED

CIN: L16004MH1936PLC008587
Regd. office: Macropolo Building, Ground Floor, Dr. Babasaheb Ambedkar Road, Lalbaug, Mumbai - 400 033
Phone: 022-6195 2300/ Fax : 022-6195 2319
Corp. office: Omaxe Square, Plot No. 14, Jasola District Centre, Jasola, New Delhi- 110025
Phone: 011- 61119300, 26832155
Email: isc@godfreyphillips.co.in **Website:** www.godfreyphillips.co.in

NOTICE TO SHAREHOLDERS

SPECIAL WINDOW FOR RE-LODGMENT OF TRANSFER REQUESTS OF PHYSICAL SHARES.

As a measure towards Ease of doing Investment, SEBI vide its circular no. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated 2nd July 2025, has opened a 'Special Window' from 7th July 2025 to 6th January 2026 for re-lodgement of transfer deeds by physical shareholders, **whose transfer deeds were lodged prior to deadline of April 1, 2019 fixed for transfer of physical shares**, and were rejected /returned due to deficiency in documents.

Shareholders of the Company, who wish to avail the opportunity of 'Special Window', can do so by re-lodging their requests, after removing the deficiency(ies), before the Company's Registrar and Transfer Agent, MUFG Intime India Private Limited at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400083, Tel. No. 022-49186270 and can get their shares issued in de-mat form only.

In case of any queries, shareholders are requested to raise a service request at https://web.in.mpms.mufg.com/helpdesk/Service_Request.html or email at rnt.helpdesk@in.mpms.mufg.com

For Godfrey Phillips India Limited
Sd/-
Pumit Kumar Chellaramani
Company Secretary & Compliance Officer

Place: Mumbai
Date: 23rd September 2025

MIRAE ASSET Mutual Fund

NOTICE NO. AD/64/2025

Declaration of Income Distribution cum Capital Withdrawal in Mirae Asset Aggressive Hybrid Fund (Erstwhile known as Mirae Asset Hybrid Equity Fund)

NOTICE is hereby given that Mirae Asset Trustee Company Pvt. Ltd., Trustees to Mirae Asset Mutual Fund ("MAMF") have approved declaration of Income Distribution cum Capital Withdrawal (IDCW) in Mirae Asset Aggressive Hybrid Fund:

Scheme / Plan / Option	Quantum** (₹ per unit)	NAV as on September 22, 2025 (₹ per unit)	Record Date*	Face Value (₹ Per Unit)
Mirae Asset Aggressive Hybrid Fund - Regular Plan - IDCW Option	0.10	17.562	Friday, September 26, 2025	10.00
Mirae Asset Aggressive Hybrid Fund - Direct Plan - IDCW Option	0.10	21.430		

* or the immediately following Business Day, if that day is not a Business day.
** subject to availability of distributable surplus as on the record date and as reduced by applicable statutory levy, if any.

Pursuant to the payment of IDCW, the NAV of the IDCW option of the above-mentioned Plans of the Schemes will fall to the extent of pay-out and statutory levy (if applicable).

Income distribution will be paid to those unitholders / beneficial owners whose names appear in the register of unit holders maintained by the Mutual Fund / statement of beneficial ownership maintained by the depositories, as applicable, under the IDCW option of the aforesaid plans as on the record date.

For and on behalf of the Board of Directors of
MIRAE ASSET INVESTMENT MANAGERS (INDIA) PVT. LTD.
(Asset Management Company for Mirae Asset Mutual Fund)

Place : Mumbai
Date : September 23, 2025

Sd/-
AUTHORISED SIGNATORY

MIRAE ASSET MUTUAL FUND (Investment Manager: Mirae Asset Investment Managers (India) Private Limited) (CIN: U65990MH2019PTC324625). Statutory Details: Sponsor: Mirae Asset Global Investments Company Limited. **Trustee:** Mirae Asset Trustee Company Private Limited.
Registered & Corporate Office: 606, 6th Floor, Windsor Building, Off CST Road, Kalina, Santacruz (E), Mumbai - 400098. ☎ 1800 2090 777 (Toll free), customercare@miraeasset.com www.miraeassetmf.co.in

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.